Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings
08:11am, Monday, 24'th May 2021
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY)
3 Dividend Stocks That Should Pay You the Rest of Your Life
06:54am, Sunday, 23'rd May 2021
It's hard to beat dividend-paying stocks -- they offer reliable income as well as stock-price appreciation.
Sanofi: Underestimated Vaccine Potential
03:47pm, Friday, 21'st May 2021
Expected approval of the COVID vaccine at the end of 2021 will allow the company to close the gap in multipliers compared to its closest competitors.
Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients
02:01pm, Thursday, 20'th May 2021
Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Societ
Better Buy for 2021: GlaxoSmithKline or Sanofi?
06:08am, Thursday, 20'th May 2021
These are two cheap stocks in an overvalued market.
Sanofi: Evaluating The Recent Dividend Hike
11:33am, Wednesday, 19'th May 2021
Sanofi has increased its annual payout by 12%+. Compared to historic trends, this increase is way above normal.
Sanofi: Our vaccine could serve as an excellent booster shot
11:16am, Tuesday, 18'th May 2021
Thomas Triomphe, EVP at Sanofi Pasteur, discusses preliminary data from a Phase 2 trial for the drugmaker's Covid-19 vaccine developed in partnership with GlaxoSmithKline.
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
11:16am, Tuesday, 18'th May 2021
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the
Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing
02:09pm, Monday, 17'th May 2021
Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to m
Sanofi Executives Say Covid Vaccine Could Be 'Universal Booster'
10:59am, Monday, 17'th May 2021
Yet competition with Pfizer and Moderna could still be stiff.
GSK and Sanofi look to catch up in vaccine race with booster doses
10:04am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market rea
GlaxoSmithKline and Sanofi plan to join vaccine race with booster doses
09:08am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market rea
Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This Year
08:21am, Monday, 17'th May 2021
A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
07:07am, Monday, 17'th May 2021
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join
GSK and Sanofi reveal positive trial results for COVID-19 vaccine
03:33am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion
